NCT07102394 2026-02-17
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
Johns Hopkins University
Phase 1 Recruiting
Clinical Trials
13 trialsNCT03554044 2025-05-21
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
Phase 1 Completed
NCT03663712 2024-11-20
TEMPO
Duke University
Phase 1 Completed
NCT03300544 2024-05-23
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT03256344 2024-05-14
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Amgen
Phase 1 Completed
NCT02756845 2024-02-20
Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors
Amgen
Phase 1 Completed
NCT04185311 2023-08-15
Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT02890368 2023-04-05
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Pfizer
Phase 1 Terminated
NCT03458117 2022-03-18
20139157 T-VEC
University of Zurich
Phase 1 Completed
NCT02626000 2021-09-08
MASTERKEY232
Amgen
Phase 1 Completed
NCT03747744 2020-12-29
myDCTV
Universitair Ziekenhuis Brussel
Phase 1 Unknown
NCT03088176 2020-10-12
Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
West Cancer Center
Phase 1 Unknown
NCT00402025 2016-04-15
Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer
BioVex Limited
Phase 1 Completed